Abstract Treatment of high-grade serous ovarian cancer (HGSOC) remains challenging.
Although HGSOC can potentially be responsive to immunotherapy owing to endogenous …

Background Immunotherapy has revolutionised the field of cancer therapy and immunology,
but has demonstrated limited therapeutic efficacy in high-grade serous ovarian cancer …

Purpose: Tumor-infiltrating lymphocytes (TIL) are associated with a better prognosis in high-
grade serous ovarian cancer (HGSC). However, it is largely unknown how this prognostic …

In the past decade, we have witnessed important gains in the treatment of ovarian cancer;
however, additional advances are required to reduce mortality. With compelling evidence …

Following a period of slow progress, the completion of genome sequencing and the
paradigm shift relative to the cell of origin for high grade serous ovarian cancer (HGSOC) led …

It is estimated that in the United States in 2018 there will be 22,240 new cases of ovarian
cancer and 14,070 deaths due to this malignancy. The most common subgroup of this …

Importance Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune
control of epithelial ovarian cancer; however, little is known about prognostic patterns of …

Background: Tumor-infiltrating lymphocytes (TILs) are involved in the antitumor immune
response. The association between prognosis in patients with TILs and high-grade serous …

Ovarian cancer, in particularly high-grade serous ovarian cancer (HGSOC) and ovarian
carcinosarcoma (OCS), are highly aggressive and deadly female cancers with limited …

Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …